J.T. Heywood
Scripps Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.T. Heywood.
Jacc-Heart Failure | 2016
Maria Rosa Costanzo; Dan Negoianu; Brian E. Jaski; Bradley A. Bart; J.T. Heywood; Inder S. Anand; James M. Smelser; Alan M. Kaneshige; Don B. Chomsky; Eric D. Adler; Garrie J. Haas; James A. Watts; Jose L. Nabut; Michael P. Schollmeyer; Gregg C. Fonarow
OBJECTIVES The AVOID-HF (Aquapheresis versus Intravenous Diuretics and Hospitalization for Heart Failure) trial tested the hypothesis that patients hospitalized for HF treated with adjustable ultrafiltration (AUF) would have a longer time to first HF event within 90 days after hospital discharge than those receiving adjustable intravenous loop diuretics (ALD). BACKGROUND Congestion in hospitalized heart failure (HF) patients portends unfavorable outcomes. METHODS The AVOID-HF trial, designed as a multicenter, 1-to-1 randomized study of 810 hospitalized HF patients, was terminated unilaterally and prematurely by the sponsor (Baxter Healthcare, Deerfield, Illinois) after enrollment of 224 patients (27.5%). Aquadex FlexFlow System (Baxter Healthcare) was used for AUF. A Clinical Events Committee, blinded to the randomized treatment, adjudicated whether 90-day events were due to HF. RESULTS A total of 110 patients were randomized to AUF and 114 to ALD. Baseline characteristics were similar. Estimated days to first HF event for the AUF and ALD group were, respectively, 62 and 34 (p = 0.106). At 30 days, compared with the ALD group, the AUF group had fewer HF and cardiovascular events. Renal function changes were similar. More AUF patients experienced an adverse effect of special interest (p = 0.018) and a serious study product-related adverse event (p = 0.026). The 90-day mortality was similar. CONCLUSIONS Compared with the ALD group, the AUF group trended toward a longer time to first HF event within 90 days and fewer HF and cardiovascular events. More patients in the AUF group experienced special interest or serious product-related adverse event. Due to the trials untimely termination, additional AUF investigation is warranted.
European Heart Journal | 2012
Wai Hong Wilson Tang; Eduardo N. Warman; James W. Johnson; Roy S. Small; J.T. Heywood
Aims Threshold crossings of impedance trends detected by implanted devices have been associated with clinically relevant heart failure events, but long-term prognosis of such events has not been demonstrated. The aim of this study is to examine the relationship between alterations in intrathoracic impedance and mortality risk in patients with implantable devices. Methods and results We reviewed remote monitoring data in the de-identified Medtronic CareLink® Discovery Link that captured intrathoracic impedance trends for >6 months. The initial 6 months of the cardiac and impedance trends were used as the observation period to create the patient groups and cross-referenced with the Social Security Death Index for mortality data. In our study cohort of 21 217 patients, 36% experienced impedance threshold crossing within the initial 6 months of monitoring (defined as the ‘early threshold crossing’ group). Patients with early threshold crossings demonstrated an increased risk of age- and gender-adjusted all-cause mortality [hazard ratio (HR) 2.15, 95% confidence interval (CI) 1.95–2.38, P< 0.0001]. Increased mortality risk remained significant when analysed in subgroups of patients without defibrillator shock (HR 2.10, 95% CI 1.90–2.34, P< 0.0001, n= 1621) or within those patients without device-detectable atrial fibrillation (AF) during the initial 6 months of monitoring (HR 2.09, 95% CI 1.86–2.34, P< 0.0001, n= 17 235). Both the number and the duration of early threshold crossings of impedance trends detectable by implanted devices were associated with increased mortality risk. Furthermore, the improvement of altered impedance trends portends more favourable prognosis. Conclusions Threshold crossing of impedance trends detectable by implanted devices is associated with relatively increased mortality risk even after adjusted for demographic, device-detected AF, or defibrillator shocks.
Current Hypertension Reviews | 2018
Muhammad Chaudhry; Allen Johnson; J.T. Heywood
OBJECTIVES Stiff left atrial syndrome is an intriguing clinical phenomena characterized by reduced left atrial compliance, pulmonary venous hypertension and exacerbations of volume overload. We conducted a retrospective review of patients diagnosed with stiff left atrial syndrome at our center. METHODS All patients admitted to our hospital with volume overload and pulmonary venous hypertension who were diagnosed with stiff left atrial syndrome based on evidence by echocardiogram and right heart catheterization between July 2011 and July 2013 were included in this retrospective review. RESULTS Twentythree patients (mean age 73 ± 11 years, 39% male and 61% female) were diagnosed with stiff left atrial syndrome at our center. Thirty-five percent had persistent while 39% had permanent atrial fibrillation. Mean duration of atrial fibrillation was 7.6 ± 2.1 years. Forty-three percent of patients had long standing hypertension. There was no mitral regurgitation in 39% of patients while 48% had mild mitral regurgitation. On right heart catheterization, mean right atrial pressure was 12.6±4.8 mm of Hg, mean pulmonary arterial pressure was 33±7.2 mm of Hg, mean pulmonary capillary wedge pressure was 24.8± 4.2mm of Hg while peak V waves were seen at mean of 37.8± 5.3 mm of Hg. Mean left atrial volume index was 49.8±17.1 mL/m 2. After the initial diagnosis with a two year follow- up, there were no readmissions in 65% of patients who were on appropriate diuretic therapy and had regular clinical visits. Frequent readmissions were seen in 35% of patients inspite of appropriate diuretic therapy. All-cause mortality rate was 4.3% at two year follow up. CONCLUSION In patients with stiff left atrial syndrome, the presence of left atrial dilation, long standing atrial fibrillation and hypertension are the key factors associated with pathogenesis and clinical course. Close follow up and monitoring of volume status is essential to prevent hospital readmissions and improve long term prognosis.
Journal of the American College of Cardiology | 2016
Christina Tan; Ajay Srivastava; David S. Rubenson; Michael R. Smith; Rajeev Mohan; Dan Meyer; Sam Baradarian; J.T. Heywood
Left ventricular outflow tract velocity time integral (LVOT VTI) correlates with stroke volume, reflecting cardiac pump systolic function. In heart failure patients with reduced LVOT VTI, extremely low LVOT VTI was hypothesized to predict increased mortality and need for left ventricular assist
Journal of Heart and Lung Transplantation | 2018
A.C. Pandey; K. Kheder; M. Pelter; Ajay Srivastava; J.T. Heywood; R. Mohan
Journal of Cardiac Failure | 2013
Muhammad Chaudhry; Allen Johnson; J.T. Heywood
Journal of Cardiac Failure | 2010
Nancy M. Albert; Anne B. Curtis; Mihai Gheorghiade; J.T. Heywood; P. Johnson Inge; Mark L. McBride; Mandeep R. Mehra; Christopher M. O'Connor; Dwight Reynolds; Mary Norine Walsh; Clyde W. Yancy; G.C. Fonarow
Journal of Cardiac Failure | 2010
Dwight Reynolds; Nancy M. Albert; Anne B. Curtis; Mihai Gheorghiade; J.T. Heywood; P. Johnson Inge; Mark L. McBride; Mandeep R. Mehra; Christopher M. O'Connor; Mary Norine Walsh; Clyde W. Yancy; G.C. Fonarow
Journal of Cardiac Failure | 2009
G.C. Fonarow; Clyde W. Yancy; Nancy M. Albert; Anne B. Curtis; W. Gattis Stough; Mihai Gheorghiade; J.T. Heywood; Mark L. McBride; Mandeep R. Mehra; C. O'Connor; Dwight Reynolds; Mary Norine Walsh
Journal of the American College of Cardiology | 2018
Rola Khedraki; Rajeev Mohan; J.T. Heywood; Ajay Srivastava